Botox

FDA Notifies Public of Adverse Reactions Linked to Botox Use

By admin - Posted on February 12th, 2008

Ongoing safety review of Botox, Botox Cosmetic and Myobloc taking place

February 8, 2008 -- The U.S. Food and Drug Administration (FDA) today notified the public that Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) have been linked in some cases to adverse reactions, including respiratory failure and death, following treatment of a variety of conditions using a wide range of doses. » read more »

Public Citizen: FDA’s Botox Warning Falls Short

By newsdesk - Posted on February 11th, 2008

Feb. 8, 2008 -- Statement of Sidney Wolfe, MD, Director of the Health Research Group at Public Citizen: » read more »

Stricter Warnings Needed for Botox, Myobloc Injections

By newsdesk - Posted on January 25th, 2008

Public Citizen Petitions FDA for ‘Black Box’ Labels, Physician and Patient Warnings; Cites Deaths Linked to Use of the Drugs

Jan. 24, 2008 -- WASHINGTON, D.C. – The Food and Drug Administration (FDA) should immediately increase its warnings and directly warn patients and doctors about the use of botulinum toxin – available as Botox and Myobloc – because of serious adverse reactions, including deaths, linked to the drug, Public Citizen said in a petition filed Thursday with the agency. » read more »